GLP-1 drugs have grown in popularity and Aspen is betting on contracts for the medications to boost future earnings. To discuss the evolution of the highly effective diabetes and obesity drugs, Business Day TV sat down with Aspen’s Stavros Nicolaou.
WATCH: Tracking the diabetes drug market
Business Day TV speaks to Stavros Nicolaou, a senior executive at Aspen
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.